Drugs.com

SEPTEMBER 14, 2024

SATURDAY, Sept. 14, 2024 -- Beans may sometimes give you gas, but one expert says that shouldn't stop you from finding ways to include them in your diet.Why? Because they are packed with nutrients that contribute to good health.“Beans are in a u.

98

98

BioPharma Drive: Drug Pricing

SEPTEMBER 14, 2024

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

Trials 74

Trials Drugs 74

Covalent Modifiers

SEPTEMBER 14, 2024

Dong, S., Huang, H., Li, J. et al. Commun Chem 7 , 201 (2024). [link] Multi-functional cysteine-targeting covalent warheads possess significant therapeutic potential in medicinal chemistry and chemical biology. Herein, we present novel unsaturated and asymmetric ketone (oxazolinosene) scaffolds that selectively conjugate cysteine residues of peptides and bovine serum albumin under normal physiological conditions.

70

70

Common Sense for Drug Policy Blog

SEPTEMBER 14, 2024

Deaths in the US Due to the Toxic Unregulated Drug Supply and Overdose, 1999-2023 dwf_admin Sat, 09/14/2024 - 07:58

Drugs 52

Drugs 52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

New Drug Approvals

SEPTEMBER 14, 2024

Zamaporvint RXC004, PHASE 2 1H-IMIDAZOLE-1-ACETAMIDE, 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)- 5-METHYL-N-(5-(2-PYRAZINYL)-2-PYRIDINYL)-4-(2-(TRIFLUOROMETHYL)-4-PYRIDINYL)-1H-IMIDAZOLE-1-ACETAMIDE UNII M56M7CHN8E Molecular Weight 439.39 Formula C 21 H 16 F 3 N 7 O CAS No. 1900754-56-4 Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt.

Pharmacokinetics 57

Pharmacokinetics Research Drugs 57